Mavorixafor
Cat. No.：YN321274
| 产品名称: | Mavorixafor |
| CAS No.: | 558447-26-0 |
| Chemical Name: | N1-(1H-benzimidazol-2-ylmethyl)-N1-[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]-1,4-butanediamine |
| Synonyms: | AMD-070 |
| 分子量: | 349.47 |
| 分子式: | C₂₁H₂₇N₅ |
| SMILES: | NCCCCN(CC1=NC2=C(N1)C=CC=C2)[C@@H]3C4=C(CCC3)C=CC=N4 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Mavorixafor (AMD-070) 是一种有效的，选择性的，可口服的CXCR4拮抗剂，能够拮抗125I-SDF 与 CXCR4 结合，IC50值为 13 nM；Mavorixafor (AMD-070) 能够抑制 HIV-1 (NL4.3 strain) 的复制，在 MT-4 和 PBMCs 细胞中，IC50值分别为 1 和 9 nM。 |
| IC50和靶点: | [{name:"125I-SDF-CXCR4:13 nM (IC50)"},{name: "HIV-1 (NL4.3 strain):1 nM (IC50, in MT-4 cells)"},{name: "HIV-1 (NL4.3 strain):9 nM (IC50, in PBMCs)"},{name: "HIV-1 (NL4.3 strain):3 nM (IC90, in MT-4 cells)"},{name: "HIV-1 (NL4.3 strain):26 nM (IC90, in PBMCs)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Skerlj, R.T., Bridger, G.J., Kaller, A., et al.Discovery of novel small molecule orally bioavailable C–X–C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replicationJ. Med. Chem.53(8),3376-3388(2010)
Mosi, R.M., Anastassova, V., Cox, J., et al.The molecular pharmacology of AMD11070: An orally bioavailable CXCR4 HIV entry inhibitorBiochem. Pharmacol.83(4),472-479(2012)
